Compare Infosys Limited (INFY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Twist Bioscience Corp — how do they compare? Infosys Limited trades at $10.95 (market cap $41.74B), while Twist Bioscience Corp trades at $155.9 (market cap $10.08B). The key difference: Infosys Limited is far larger — about 4.1× Twist Bioscience Corp's market cap, and Infosys Limited pays a 4.89% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Twist Bioscience Corp for 27 Days on average.
| INFY | TWST | |
|---|---|---|
Market Cap | $41.74B | $10.08B |
Volume | 31,354,285 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $20.22 | $205.00 |
52-Week Low | $10.49 | $25.45 |
Typical Hold Time | 27 Days | 27 Days |
Enterprise Value | $39.48B | $10.01B |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Infosys (INFY) trades at $10.55, showing no change in the latest session. The stock is in a bearish technical trend with key support at $10 and resistance at $11. Fundamentally, the company reported strong profitability with a net income margin of 16.37% and ROE of 32.12% for 2025. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro, to drive innovation. However, cash flow trends show a projected decline in net cash flow for 2026.
The outlook for INFY is mixed. Positive fundamentals and strategic partnerships offer growth potential, but bearish technicals and a projected cash flow decline pose risks. Analyst consensus is a 'Hold' with a price target of $11.48, suggesting limited near-term upside. Investors should weigh strong profitability against execution risks in a competitive IT services market.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
